Fulcrum Therapeutics (NASDAQ:FULC) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Fulcrum Therapeutics (NASDAQ:FULC) issued its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.13), FiscalAI reports.

Fulcrum Therapeutics Stock Up 2.8%

FULC stock traded up $0.10 during trading on Thursday, hitting $3.72. 1,124,947 shares of the company’s stock traded hands, compared to its average volume of 1,454,950. The firm has a market capitalization of $247.86 million, a P/E ratio of -3.23 and a beta of 3.01. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The business has a fifty day simple moving average of $4.05 and a two-hundred day simple moving average of $6.95.

Analyst Ratings Changes

FULC has been the topic of a number of analyst reports. Piper Sandler cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Tuesday, June 2nd. Cantor Fitzgerald lowered Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. JPMorgan Chase & Co. downgraded Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Wednesday, June 3rd. Finally, Jefferies Financial Group set a $4.00 price objective on Fulcrum Therapeutics in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $8.20.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director owned 10,927 shares in the company, valued at $39,883.55. This represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. purchased a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth $39,000. Quarry LP purchased a new position in Fulcrum Therapeutics in the third quarter valued at about $35,000. Persistent Asset Partners Ltd bought a new position in Fulcrum Therapeutics in the fourth quarter worth about $75,000. Russell Investments Group Ltd. lifted its position in shares of Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after buying an additional 9,092 shares during the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at about $136,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.